Asian Phytoceuticals Valuation
Is APCO-R undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of APCO-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: APCO-R (THB6.45) is trading above our estimate of fair value (THB1.78)
Significantly Below Fair Value: APCO-R is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for APCO-R?
Other financial metrics that can be useful for relative valuation.
What is APCO-R's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ฿3.87b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 13.8x |
Enterprise Value/EBITDA | 35.7x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does APCO-R's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 26.9x | ||
KISS Rojukiss International | 22.6x | 14.4% | ฿3.1b |
TNR Thai Nippon Rubber Industry Public | 12.4x | n/a | ฿3.4b |
IP Inter Pharma | 61.4x | n/a | ฿3.2b |
S&J S & J International Enterprises | 11.3x | n/a | ฿7.9b |
APCO-R Asian Phytoceuticals | 42.3x | n/a | ฿3.9b |
Price-To-Earnings vs Peers: APCO-R is expensive based on its Price-To-Earnings Ratio (42.3x) compared to the peer average (26.9x).
Price to Earnings Ratio vs Industry
How does APCO-R's PE Ratio compare vs other companies in the Asian Personal Products Industry?
Price-To-Earnings vs Industry: APCO-R is expensive based on its Price-To-Earnings Ratio (42.3x) compared to the Asian Personal Products industry average (25x).
Price to Earnings Ratio vs Fair Ratio
What is APCO-R's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 42.3x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate APCO-R's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.